Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
15:23:33 EDT Sun 05 May 2024
Enter Symbol
or Name
USA
CA



News for U:ALPN from 2023-05-04 to 2024-05-03 - 31 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-04-10 16:15U:ALPNNews ReleaseAlpine Immune Sciences Shares Updated Clinical Data from Povetacicept in IgA Nephropathy
2024-04-10 16:01U:ALPNNews ReleaseVertex Enters Into Agreement to Acquire Alpine Immune Sciences
2024-04-10 16:01U:ALPNNews ReleaseVertex Enters Into Agreement to Acquire Alpine Immune Sciences
2024-04-01 09:00U:ALPNNews ReleaseAlpine Immune Sciences to Present Updated Clinical Data for Povetacicept in IgA Nephropathy at the World Congress of Nephrology 2024
2024-03-21 07:45U:ALPNNews ReleaseAlpine Immune Sciences Presents New Translational Data on Povetacicept at the European Lupus Meeting 2024
2024-03-20 16:30U:ALPNNews ReleaseAlpine Immune Sciences to Participate in Upcoming H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
2024-03-18 16:05U:ALPNNews ReleaseAlpine Immune Sciences Provides Corporate Update and Full Year 2023 Financial Results
2024-03-07 16:30U:ALPNNews ReleaseAlpine Immune Sciences to Report Fourth Quarter and Full Year 2023 Financial Results
2024-02-26 16:30U:ALPNNews ReleaseAlpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences
2024-02-01 16:30U:ALPNNews ReleaseAlpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences
2023-12-21 16:15U:ALPNNews ReleaseAlpine Immune Sciences Announces Amendment of Acazicolcept Option and License Agreement with AbbVie
2023-12-18 16:30U:ALPNNews ReleaseAlpine Immune Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-11-20 16:30U:ALPNNews ReleaseAlpine Immune Sciences to Participate in the Evercore ISI HealthconX Conference
2023-11-15 09:00U:ALPNNews ReleaseAlpine Immune Sciences Presents New Translational Data on Povetacicept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023
2023-11-14 16:15U:ALPNNews ReleaseAlpine Immune Sciences Reports Third Quarter 2023 Financial Results
2023-11-13 09:00U:ALPNNews ReleaseAlpine Immune Sciences Presents New Translational Data on Acazicolcept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023
2023-11-06 21:41U:ALPNNews ReleaseAlpine Immune Sciences Announces Pricing of $150 Million Public Offering
2023-11-06 06:00U:ALPNNews ReleaseAlpine Immune Sciences Announces Proposed Public Offering
2023-11-03 09:00U:ALPNNews ReleaseAlpine Immune Sciences Presents New Preclinical Data on Povetacicept in Myasthenia Gravis at the American Association of Neuromuscular & Electrodiagnostic Medicine 2023 Annual Meeting
2023-11-02 09:00U:ALPNNews ReleaseAlpine Immune Sciences Presents Initial Clinical Data on Povetacicept in Autoimmune Glomerulonephritis in a Late-Breaking Poster Session at the American Society of Nephrology Kidney Week 2023
2023-10-30 09:00U:ALPNNews ReleaseAlpine Immune Sciences to Present New Translational Data on Povetacicept and Acazicolcept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023
2023-10-13 09:05U:ALPNNews ReleaseAlpine Immune Sciences to Present Initial Clinical Data on Povetacicept in Autoimmune Glomerulonephritis in a Late Breaker Poster Session at American Society of Nephrology Kidney Week 2023
2023-10-04 08:00U:ALPNNews ReleaseAlpine Immune Sciences Announces Appointment of Wolfgang Dummer, M.D., Ph.D., as Chief Medical Officer and Grant under Nasdaq Listing Rule 5635(c)
2023-09-12 08:30U:ALPNNews ReleaseAlpine Immune Sciences Presents First Preclinical Data for Povetacicept in Myasthenia Gravis at the American Neurological Association Annual Meeting
2023-09-05 16:30U:ALPNNews ReleaseAlpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences
2023-09-05 08:30U:ALPNNews ReleaseAlpine Immune Sciences to Present First Preclinical Data for Povetacicept in Myasthenia Gravis at the American Neurological Association Annual Meeting
2023-08-30 16:30U:ALPNNews ReleaseAlpine Immune Sciences Announces Initiation of Dosing in 240 mg IgA Nephropathy Cohort of Povetacicept Clinical Study (RUBY-3)
2023-08-22 16:30U:ALPNNews ReleaseAlpine Immune Sciences Announces Appointment of M. Christina Yi as Chief Technology Officer and Grant under Nasdaq Listing Rule 5635(c)
2023-08-14 16:15U:ALPNNews ReleaseAlpine Immune Sciences Reports Second Quarter 2023 Financial Results
2023-05-19 16:30U:ALPNNews ReleaseAlpine Immune Sciences to Present Data from RUBY-1, a Phase 1 Study of Povetacicept, at Upcoming Scientific Congresses
2023-05-11 16:15U:ALPNNews ReleaseAlpine Immune Sciences Reports First Quarter 2023 Financial Results